Abstract: Provided are a brucine gel plaster and a preparation method therefor. The brucine gel plaster comprises, calculated by weight percentage, 0.3%-2% of brucine, 3%-10% of a framework material, 20%-50% of a humectant and a co-solvent, 0.1%-2% of a crosslinking agent and a crosslinking regulator, and the balance of water, as well as a backing layer and an anti-adhesive layer. The brucine gel plaster uses simple medicinal excipients, does not use a transdermal enhancer, has good skin compatibility, is moisturizing and breathable, is non-irritating to the skin and mucous membranes, has a large drug load, and can be applied to repeatedly. The plaster is used for treating or ameliorating related diseases requiring anti-inflammation and analgesia such as osteoarthritis, rheumatic arthritis and rheumatoid arthritis.

Abstract: A brucine gel formulation, a preparation method therefor and use thereof. Said gel formulation comprises 0.5%-1% of brucine, 0.5%-3% of a gel matrix and 10%-30% of a co-solvent. Said brucine hydrogel does not contain a transdermal enhancer, but has an excellent transdermal effect, is easy to coat, has good biosolubility, good skin absorption and good drug film adhesion, and is non-irritating to the skin and mucosa.

Abstract: Provided are a Rho kinase inhibitor, a method for preparing same and the uses thereof. The Rho kinase inhibitor designates a compound of Formula I, a stereoisomer thereof or pharmaceutically acceptable salt thereof. The Rho kinase inhibitor promotes endothelial cells and endothelin expression, prostenin expression, and vascular factors NO synthesis and secretion, has a promoting effect on proprostin expression independently of the doses used, shows lower toxicity, while being safer.